Credit: Unsplash/CC0 Public Domain The early treatment of obesity in children is effective in both the short and long term, researchers from Karolinska Institutet report in a study published in The International Journal of Obesity. The researchers followed over 170 young children in Sweden who had received treatment for diagnosed obesity. The children were recruited …
Early treatment of child obesity found effective Read More »
Credit: Pixabay/CC0 Public Domain Bystanders are less likely to give cardiopulmonary resuscitation (CPR) to women than men, particularly if the emergency takes place in a public area, according to research presented at the European Emergency Medicine Congress. The study also shows that in private locations older people, especially older men, are less likely to receive …
Women less likely than men to be given CPR in public places, research finds Read More »
Credit: Pixabay/CC0 Public Domain A novel study has shown that Senolytics, a new class of drugs, have the potential to prevent the transfer of senescence, a key mechanism of aging, and the associated physical and cognitive impairments in recipients of older donor organs. The pioneering research, presented at the European Society for Organ Transplantation (ESOT) …
Transfer of aging: New drug class prevents key aging mechanism in organ transplants Read More »
Credit: Pixabay/CC0 Public Domain If doctors in hospital emergency departments are trained to carry out ultrasound on patients with suspected deep vein thrombosis (DVT), they can nearly halve the time the patients spend in these departments. Dr. Ossi Hannula, an emergency medicine specialist at the Well-being Services County of Central Finland, Jyväskylä, Finland, who presented …
Credit: CC0 Public Domain The head of the World Health Organization told the Financial Times he was ready to send a new mission of experts to China to investigate the origins of COVID-19. “We’re pressing China to give full access, and we are asking countries to raise it during their bilateral meetings—(to urge Beijing) to …
WHO calls on China for ‘full access’ for COVID investigators: FT Read More »
Leverkusen, April 28, 2023 – Bayer strengthened its position as a successful life science company in 2022 despite the difficult conditions. “We now need to build on these strong foundations and set the course for future growth,” CEO Werner Baumann said at the company’s virtual Annual Stockholders’ Meeting in Leverkusen on Friday. “The need is …
01 March 2023 | 07:59 AM Europe/Amsterdam Not intended for U.S. and UK Media Summary Submission to the Ministry of Health, Labor, and Welfare (MHLW) in Japan for aflibercept 8 mg in neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) is based on positive results of phase III clinical trials, PULSAR and …
Bayer submits aflibercept 8 mg for marketing authorization in Japan Read More »
Not intended for U.S. and UK Media Berlin, March 1, 2023 – The European Commission has granted marketing authorization in the European Union (EU) for Nubeqa™ (darolutamide), an oral androgen receptor inhibitor (ARi), plus androgen deprivation therapy (ADT) in combination with docetaxel, for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). Nubeqa is …
Nubeqa™ (darolutamide) receives EU approval for additional indication in prostate cancer Read More »
Leverkusen, February 28, 2023 – The Bayer Group achieved strong growth last year, posting significantly higher sales and earnings. “2022 was a very successful year for Bayer despite the challenging environment. We were able to deliver, even during these difficult times, and met the upgraded financial targets we set in August,” said Werner Baumann, Chairman …
Not intended for U.S. and UK Media Berlin, February 27, 2023 – The Ministry of Health, Labor and Welfare (MHLW) in Japan has approved the oral androgen receptor inhibitor (ARi) darolutamide plus ADT in combination with docetaxel in the indication of metastatic prostate cancer. The MHLW approval is based on the positive results from the …
Nubeqa™ approved for additional indication in Japan Read More »